#None #GEP #Granata Bio #FSH #Boston, Denver

Granata Bio Corporation and Georgetown Equity Partners Announce Joint Venture for Innovative FSH Development

In a groundbreaking partnership, Granata Bio Corporation, a pioneering biotechnology firm focused on fertility solutions, and Georgetown Equity Partners (GEP) revealed today the establishment of GTE Bio, LLC. This joint venture aims to develop a next-generation form of follicle-stimulating hormone (FSH), specifically a hypoglycosylated version. This new approach leverages intellectual property licensed from the prestigious University of Colorado Anschutz.

Redefining FSH for Enhanced Efficacy

The foundation of this joint venture is grounded in years of research demonstrating that glycosylation, the process by which sugar molecules attach to proteins, significantly influences the safety, efficacy, and immunogenicity of gonadotropin hormones like FSH. Current recombinant FSH products available on the market are fully glycosylated, imitating older hormonal preparations sourced from postmenopausal urine. In contrast, research indicates that women of reproductive age display a predominance of hypoglycosylated FSH forms.

Dr. T. Rajendra Kumar, a leading researcher at the University of Colorado Anschutz, emphasized the implications of their findings, stating, "Our studies utilizing mouse genetic models have revealed that hypoglycosylated FSH optimizes intracellular signaling pathways. This enhancement translates to improved downstream activity and better granulosa cell function than its menopausal counterpart. These promising results suggest a potential for enhanced follicular recruitment alongside a greater yield of top-quality oocytes, and may even lead to increased estrogen production."

Aiming for Refined Fertility Treatments

GTE Bio, LLC will allow Granata Bio to spearhead critical development efforts, overseeing all aspects of chemistry, manufacturing, and preclinical as well as clinical programs. This initiative led by Granata Bio is primarily focused on advancing hypoglycosylated FSH to clinical trials, paving the way for its introduction into human treatment cycles.

Dr. William Schoolcraft, Founder of GEP and a respected voice in reproductive medicine, expressed his enthusiasm, stating, "Having closely followed Dr. Kumar's work for years, I am thrilled to assist in the translation of his innovative research into viable therapeutic options for patients. Granata Bio's leadership in developing fertility medications positions us perfectly to meet the needs of reproductive health."

CEO Evan Sussman of Granata Bio shared his vision for the future of fertility treatments, noting, "We are committed to investing in initiatives that improve patient outcomes. Our quest for a better FSH variant is rooted in a deep understanding of reproductive biology, offering significant potential to enhance outcomes in in vitro fertilization (IVF) procedures."

About the Companies Involved

Granata Bio Corporation, established in 2018, is determined to redefine reproductive health for families through pioneering advancements in fertility treatments. The firm prides itself on its extensive knowledge base, robust partnerships, and steady progress in achieving key milestones across its innovative product pipeline. For more information, visit www.granata.bio.

Georgetown Equity Partners, led by Dr. Schoolcraft, is a prominent investment firm that collaborates with innovators in the life sciences, medical technology, and healthcare sectors. Their expertise lies in scaling transformative companies that can make meaningful impacts on patient care. To learn more, please visit www.gtepartners.com.